Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![MSollender Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1063180083769176064.png) Michelle Solly [@MSollender](/creator/twitter/MSollender) on x 13.1K followers
Created: 2025-07-22 20:12:22 UTC

$ABVX Abivax Announces  Positive Phase X Results from Both ABTECT 8-Week Induction Trials  Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in  Moderate to Severely Active Ulcerative Colitis




XXXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947751594671673714/c:line.svg)

**Related Topics**
[$abvx](/topic/$abvx)

[Post Link](https://x.com/MSollender/status/1947751594671673714)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

MSollender Avatar Michelle Solly @MSollender on x 13.1K followers Created: 2025-07-22 20:12:22 UTC

$ABVX Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

XXXXXX engagements

Engagements Line Chart

Related Topics $abvx

Post Link

post/tweet::1947751594671673714
/post/tweet::1947751594671673714